PureTech Health plc
PTCHF
Other OTC1.60
USD
- -
- -
PureTech Health plc
PTCHF
(Other OTC)
Recent
price
1.60
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- PureTech Health plc operates as a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for complex diseases with significant unmet medical needs. The company’s product portfolio includes wholly owned therapeutic candidates such as deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis and other fibrotic lung diseases; LYT-200, a fully human IgG1 monoclonal antibody targeting PD-L1 and TGFβ for solid tumors including pancreatic, colorectal, and head and neck cancers; and LYT-300, an oral allopregnanolone prodrug for anxiety disorders and postpartum depression. Additionally, PureTech supports its Founded Entities including Vedanta Biosciences, which develops live biotherapeutic products for immuno-oncology, inflammatory bowel disease, and food allergies; Karuna Therapeutics, focused on psychiatric and neurological conditions; Sonde Health, specializing in vocal biomarker technology; and digital therapeutics company Akili Interactive, owner of EndeavorRx for ADHD treatment. The company operates primarily in the US and UK markets and maintains a hub-and-spoke business model that incubates and advances novel technologies through spin-out entities. Founded in 1998 and headquartered in Boston, Massachusetts, PureTech Health leverages its proprietary R&D and capital-efficient hub-and-spoke model to identify and clinically de-risk high-potential programs and then scale them through its portfolio companies with external capital support. In recent developments through 2024 and 2025, PureTech launched Celea Therapeutics to advance deupirfenidone (LYT-100), a Phase 3-ready candidate expected to initiate trials in the first half of 2026, and secured FDA approval milestones such as the approval of Cobenfy (formerly KarXT) for schizophrenia, now marketed by Bristol Myers Squibb following Karuna Therapeutics’ acquisition. PureTech continues to refine its operational strategy by transitioning responsibilities for certain programs to their respective Founded Entities, aiming to reduce operational expenses by 2026 while maintaining innovation capacity. The company also achieved a 45% revenue increase in 2024, driven by contract milestones and maintains a strong cash position supporting operations into 2027 and beyond. PureTech's portfolio extends across immunology, neurological disorders, oncology, inflammatory conditions, and psychiatric illnesses with a commitment to cutting-edge biotechnology platforms including microbiome therapeutics and engineered cellular therapies. The company’s ongoing strategic priorities emphasize advancing clinical programs with patient-centered urgency, securing external financing for late-stage trials, and leveraging partnerships and divestitures to maximize value creation for shareholders. PureTech Health's management team includes industry veterans leading a diversified pipeline and expanding its footprint in the biopharma innovation ecosystem through focused investments and strategic collaborations.
PureTech Health: Results of Annual General Meeting
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
PureTech Health plc (PRTC) Q4 2025 Earnings Call Transcript
Short Interest in PureTech Health plc (OTCMKTS:PTCHF) Expands By 69.4%
Cavendish sees Poolbeg’s POLB 001 gaining strategic importance as CRS research expands
Greengage plans AQSE float with bold Bitcoin-backed lending strategy
Puretech gains after FDA meeting post-Phase II trial
Coinsilium notes Greengage’s plan to float on Aquis